AIDA Awards

Artificial-Intelligence Designed Antibody Awards

  • Revolution

    Revolution

    Join the AI-based Ab design revolution and access to disruptive technology

  • Swift

    Swift

    Get your antibodies candidates in days to start your biological assays !

  • Free to operate Ab

    Free-to-Operate Ab

    Winners will get license-free sequences/antibodies, with an open shared IP model

  • No nagging but support!

    No nagging
    but support!

    You can count on our help, guidance and expertise to design your antibody leads

  • What is the AIDA Awards program?

    What is the AIDA Awards program?

    The AIDA Awards program aims at providing scientists with AI-designed antibodies, or sequences, ready for biological assays, worth thousands of euros, entirely covered by MAbSilico.

    The AIDA Awards program aims at providing scientists with AI-designed antibodies, or sequences, ready for biological assays, worth thousands of euros, entirely covered by MAbSilico.

    The AIDA Awards 2022 is the first edition and celebrates the 5th anniversary of MAbSilico. During these years, MAbSilico has supported startup, biotech and biopharma companies in their drug discovery programs.

    MAbSilico is revolutionizing the antibody drug discovery process by designing with AI antibodies that meet the criteria of efficacy, specificity, manufacturability and safety. We have analyzed more than 100 million antibody sequences, and selected batches of candidates on various targets, some of which are in preclinical and clinical development today.

    The AIDA Awards is a unique opportunity for scientists from academia, biotech, and startups to collaborate with MAbSilico. Choose your target of interest and receive novel AI-designed novel antibodies!

  • Why participate in the AIDA program?

    Why participate in the AIDA program?

    Together, we can revolutionize the process for drug discovery and development to provide new drugs for patients by using in silico design of antibodies for binding therapeutic targets.

    Together, we can revolutionize the process for drug discovery and development to provide new drugs for patients by using in silico design of antibodies for binding therapeutic targets.

    We are also biologists at MAbSilico and we know how long and difficult it can be to generate antibodies against a protein of interest. MAbSilico technologies proved their capability to identify antibodies faster than any experimental method. The purpose of the AIDA Awards is to provide antibodies designed with state-of-the-art and exclusive AI-based technologies for antibody design.

  • What types of projects are considered?

    What types of projects are considered?

    MAbSilico will consider any project that could benefit from our expertise and technology. A project’s application may refer to any research area, any antibody format including VHH, Fab, full IgG, ADC, scFv (for CAR-T cell or not) or also new administration systems like mRNA.

    MAbSilico will consider any project that could benefit from our expertise and technology. A project’s application may refer to any research area, any antibody format including VHH, Fab, full IgG, ADC, scFv (for CAR-T cell or not) or also new administration systems like mRNA.

    The only strictly mandatory information needed for MAbSilico is the name of your target of interest. Our scientific team can often aid in the identification of appropriate structural data, homology model templates, and potential binding sites when reviewing an application. Keep in mind that we can work on any type of target, whether it is soluble, transmembrane, multimeric etc., as long as it is a protein.

    All the provided antibodies must be physically verified by a lab assay and this is your expertise and capabilities that will be the key for the success of the AIDA Awards!

We are agnostic !

We can work on...

  • What is the AIDA Awards program?

    What is the AIDA Awards program?

    The AIDA Awards program aims at providing scientists with AI-designed antibodies, or sequences, ready for biological assays, worth thousands of euros, entirely covered by MAbSilico.

  • Why participate in the AIDA program?

    Why participate in the AIDA program?

    Together, we can revolutionize the process for drug discovery and development to provide new drugs for patients by using in silico design of antibodies for binding therapeutic targets.

  • What types of projects are considered?

    What types of projects are considered?

    MAbSilico will consider any project that could benefit from our expertise and technology. A project’s application may refer to any research area, any antibody format including VHH, Fab, full IgG, ADC, scFv (for CAR-T cell or not) or also new administration systems like mRNA.

Awardees prize

  • 10 different antibodies

    Up to 10 different
    antibodies (as purified protein)

    …binding to the target of interest on a defined epitope having a KD in the nanomolar range.

  • Expertise and support

    MAbSilico expertise and
    support

    …from our pluri-disciplinary team of biologists, computer and data scientists all along the program

Awards timeline

Time to receive antibodies can vary but many projects have antibodies in their lab for testing within 2 months of receiving notice of an award.

  • Application start

    Application start

    July 01, 2022

  • Application deadline

    Application deadline

    September 16, 2022

  • Announcement of 20 Nominees

    Announcement of 20 Nominees

    October 2022

  • Announcement of the 10 Winners

    Announcement of the 10 Winners

    Late November 2022

Download the archive with every
documents from the AIDA awards

Download archive

Grant Application form

Project name

Applicant information



If student or post-doctoral fellow:

note: you are asked to join an approval letter from your PI

Organization


How did you hear about MAbSilico and the present grant?

Have you worked with MAbSilico before?


Project description

Research Area (Please select)

Short description of your project including why antibodies are central to your approach and your target of interest

Projected use of the antibody



Something not clear? Check the FAQ, otherwise send us an email to contact@mabsilico.com

  • How is intellectual property (IP) handled for the selected projects?

    Referring to the template agreement, each party owns any solely created IP and both parties will own any jointly invented IP. We know that applicants’ institutions and companies may have different needs regarding IP ownership, and MAbSilico is happy to discuss this with you.

  • Can I publish the results of an AIDA Awards project?

    We love science and we love promoting successful projects, we are therefore happy to support the publication of results. We only ask the scientist to notify us of any publication or communication so that we can share the news of your success and that authorship be determined according to typical scientific practices.

  • How long does it take to fill out an application?

    Most scientists complete the application in less than 1 hour.

  • Who can apply?

    All scientists from a non-profit university, research institution, startup or biotech.

  • Can I apply even as a graduate student or postdoc?

    For sure!!! As far as you are supported by a PI for your project.

  • Do I need to sign the research agreement before I apply?

    No. Only after you are selected for the AIDA award, we will reach out to your technology transfer office to work out the agreement.

  • What if I missed the deadline?

    You can get in touch with MAbSilico at any time contact@mabsilico.com. Other opportunities can be available.

  • Can I submit more than one application?

    Why not?! But start focusing on one 😉

  • Will you share the information in my application with others?

    No.

  • Could MAbSilico work on the same target with other researchers?

    Yes, no exclusivity on a target can be waived. We don’t use confidential information from one project in any other project.

  • Does MAbSilico provide funding or financial support as part of an AIDA Award?

    No, but a limited number of projects may receive in-kind support for assays.

  • What is the timeline?

    Application deadline: September 16, 2022
    Announcement of recipients: November 2022

    Time to receive antibodies can vary but many projects have antibodies in their lab for testing within 2 months of receiving notice of an award.

  • Who can I contact for further information and assistance?

    Reach out to MAbSilico team at contact@mabsilico.com